

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. A targeted therapeutic agent comprising:
a targeting entity which binds to a site of pathology;
a linking carrier; and
a therapeutic entity.
2. The targeted therapeutic agent of Claim 1, wherein the targeting entity binds to neovasculature associated with a site of pathology.
3. (cancelled)
4. (cancelled)
5. The targeted therapeutic agent of claim 1, wherein the site of pathology is a tumor.
6. The targeted therapeutic agent of claim 1, wherein the targeting entity is an antibody.
7. The targeted therapeutic agent of claim 6, wherein the antibody is directed against the marker $\alpha_v\beta_3$.
8. The targeted therapeutic agent of claim 6, wherein the antibody is selected from the group consisting of an anti-ICAM-1 antibody, an LM609 antibody and a Vitaxin antibody.
- 9.-12. (cancelled)

13. The targeted therapeutic agent of claim 1, wherein the linking carrier is selected from the group consisting of liposomes, polymerized liposomes, other lipid vesicles, dendrimers, polyethylene glycol assemblies, polylysines, capped polylysines, poly(hydroxybutyric acid), dextrans, and coated polymers.

14. The targeted therapeutic agent of claim 1, wherein the linking carrier imparts a property to the agent selected from the group consisting of multivalency, enhanced circulation lifetimes, and increased payload. .

15.-22. (cancelled)

23. A method of treating a disease accompanied by neovascularization, said disease selected from the group consisting of cancer, solid tumors, leukemias; tumor metastasis; benign tumors, hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; rheumatoid arthritis; psoriasis; chronic inflammation; ocular angiogenic diseases, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrothalamic fibroplasia, rubeosis; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; myocardial angiogenesis; plaque neovascularization; telangiectasia; hemophiliac joints; angiofibroma; and wound granulation, comprising the step of administering the targeted therapeutic agent of claim 1 to a subject in need of such administration.

24. The method of claim 23, wherein the step of administering the targeted therapeutic agent compromises the integrity of the vasculature associated with the pathology.

25. (cancelled)

26. (cancelled)

27. The method of claim 23, further comprising the step of administering an additional therapeutic agent simultaneously with or subsequent to the administering of the targeted therapeutic agent.

28. The method of claim 24, further comprising the step of administering an additional therapeutic agent simultaneously with or subsequent to the administering of the targeted therapeutic agent.

29.-32. (cancelled)